About Scpharmaceuticals (NASDAQ:SCPH)
scPharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting. in March 2014. The company was founded in 2013 and is based in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCPH
CUSIPN/A
Phone617-517-0730
Debt
Debt-to-Equity Ratio0.09%
Current Ratio24.12%
Quick Ratio24.12%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.02 per share
Price / Book1.69
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees29
Outstanding Shares18,530,000
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) posted its quarterly earnings data on Tuesday, March, 20th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.27. View Scpharmaceuticals' Earnings History.
What price target have analysts set for SCPH?
3 equities research analysts have issued twelve-month price objectives for Scpharmaceuticals' stock. Their forecasts range from $20.00 to $26.00. On average, they expect Scpharmaceuticals' stock price to reach $23.3333 in the next year. View Analyst Ratings for Scpharmaceuticals.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include GTX (GTXI), Dermira (DERM), Clearside Biomedical (CLSD), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), Merus (MRUS), Kadmon (KDMN), Catalyst Biosciences (CBIO), Durect (DRRX), Seres Therapeutics (MCRB), Celyad (CYAD), AVEO Pharmaceuticals (AVEO), BioSpecifics Technologies (BSTC), Zymeworks (ZYME), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Avadel Pharmaceuticals (AVDL) and Savara (SVRA).
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO & Director (Age 55)
- Dr. Troy A. Ignelzi, Chief Financial Officer (Age 50)
- Mr. Abraham Ceesay, Chief Operating Officer (Age 40)
- Dr. Pieter Muntendam M.D., Consultant (Age 60)
- Katherine Taudvin, Director of Corp. Devel.
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
When does Scpharmaceuticals' lock-up period expire?
Scpharmaceuticals' lock-up period expires on Wednesday, May 16th. Scpharmaceuticals had issued 6,400,000 shares in its public offering on November 17th. The total size of the offering was $89,600,000 based on an initial share price of $14.00. After the expiration of Scpharmaceuticals' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Has Scpharmaceuticals been receiving favorable news coverage?
News stories about SCPH stock have been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Scpharmaceuticals earned a news sentiment score of 0.19 on Accern's scale. They also gave news stories about the company an impact score of 42.41 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $10.19.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $188.87 million. The company earns $-23,810,000.00 in net income (profit) each year or ($8.04) on an earnings per share basis. Scpharmaceuticals employs 29 workers across the globe.
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Scpharmaceuticals (NASDAQ:SCPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Scpharmaceuticals in the last 12 months. Their average twelve-month price target is $23.3333, suggesting that the stock has a possible upside of 128.98%. The high price target for SCPH is $26.00 and the low price target for SCPH is $20.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.3333 | $23.3333 | $22.3333 | N/A |
| Price Target Upside: | 128.98% upside | 75.04% upside | 49.69% upside | N/A |
Scpharmaceuticals (NASDAQ:SCPH) Consensus Price Target History
Scpharmaceuticals (NASDAQ:SCPH) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Scpharmaceuticals (NASDAQ:SCPH) Earnings History and Estimates Chart
Scpharmaceuticals (NASDAQ:SCPH) Earnings Estimates
2018 EPS Consensus Estimate: ($3.03)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 2 | ($0.52) | ($0.50) | ($0.51) |
| Q2 2018 | 2 | ($0.63) | ($0.58) | ($0.61) |
| Q3 2018 | 2 | ($1.33) | ($0.67) | ($1.00) |
| Q4 2018 | 2 | ($0.97) | ($0.86) | ($0.92) |
Scpharmaceuticals (NASDAQ SCPH) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/20/2018 | Q4 2017 | ($0.5270) | ($0.80) | | | View | N/A |  |
(Earnings results data provided by Zacks Investment Research)
Scpharmaceuticals (NASDAQ:SCPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Scpharmaceuticals (NASDAQ SCPH) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 42.03%
Scpharmaceuticals (NASDAQ SCPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2017 | 5Am Partners Iv, Llc | Major Shareholder | Buy | 654,762 | $14.00 | $9,166,668.00 | | |
(Data available from 1/1/2013 forward)
Scpharmaceuticals (NASDAQ SCPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Q1 2018 EPS Estimates for Scpharmaceuticals Inc Cut by Analyst (SCPH)
www.americanbankingnews.com - April 18 at 7:42 AM |
| Zacks: Scpharmaceuticals Inc (SCPH) Given $23.33 Consensus Price Target by Brokerages
www.americanbankingnews.com - April 18 at 1:18 AM |
 | Biotech Guru Samuel Isaly Bets on scPharmaceuticals (SCPH), Throws in the Towel on Synergy Pharmaceuticals (SGYP)
finance.yahoo.com - April 11 at 8:24 AM |
| -$0.51 EPS Expected for Scpharmaceuticals Inc (SCPH) This Quarter
www.americanbankingnews.com - April 6 at 11:27 AM |
| Do Scpharmaceuticals (SCPH) and Rigel Pharmaceuticals (RIGL) Have Winning Catalysts Ahead? Analysts Say Yes
finance.yahoo.com - April 4 at 4:18 PM |
| Analysts Anticipate Scpharmaceuticals Inc (SCPH) to Post ($0.51) EPS
www.americanbankingnews.com - April 3 at 1:24 PM |
| Scpharmaceuticals (SCPH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 28 at 10:48 AM |
| Leerink Swann Weighs in on Scpharmaceuticals Inc's Q1 2018 Earnings (SCPH)
www.americanbankingnews.com - March 26 at 1:02 AM |
| FY2022 Earnings Estimate for Scpharmaceuticals Inc (SCPH) Issued By Leerink Swann
www.americanbankingnews.com - March 23 at 4:58 PM |
| Scpharmaceuticals Inc (SCPH) to Post FY2019 Earnings of ($2.36) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 23 at 2:56 PM |
| Scpharmaceuticals (SCPH) Issues Quarterly Earnings Results, Misses Estimates By $0.27 EPS
www.americanbankingnews.com - March 22 at 11:50 PM |
| Jefferies Group Weighs in on Scpharmaceuticals Inc's FY2021 Earnings (SCPH)
www.americanbankingnews.com - March 22 at 5:52 PM |
| Scpharmaceuticals (SCPH) Earns Buy Rating from Jefferies Group
www.americanbankingnews.com - March 21 at 4:00 PM |
| scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 21 at 8:42 AM |
| Zacks: Brokerages Anticipate Scpharmaceuticals Inc (SCPH) to Post -$0.53 EPS
www.americanbankingnews.com - March 20 at 11:31 AM |
| Zacks: Scpharmaceuticals Inc (SCPH) Given $22.33 Average Target Price by Brokerages
www.americanbankingnews.com - March 19 at 3:22 AM |
 | scPharmaceuticals (SCPH) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:17 PM |
| AWM Investment Company Inc. Acquires Shares of 165,100 Scpharmaceuticals Inc (SCPH)
www.americanbankingnews.com - March 6 at 4:45 AM |
| Brokerages Anticipate Scpharmaceuticals Inc (SCPH) Will Announce Earnings of -$0.53 Per Share
www.americanbankingnews.com - March 3 at 10:12 AM |
| Brokerages Anticipate Scpharmaceuticals Inc (SCPH) to Post ($0.53) Earnings Per Share
www.americanbankingnews.com - March 3 at 5:28 AM |
| scPharmaceuticals Inc. to Present at the Cowen 38th Annual Health Care Conference
finance.yahoo.com - March 1 at 8:11 AM |
| scPharmaceuticals (SCPH) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:20 PM |
| Analysts Set $22.33 Target Price for Scpharmaceuticals Inc (SCPH)
www.americanbankingnews.com - February 16 at 10:28 AM |
| ScPharmaceuticals: Time For The PDUFA Run-Up
seekingalpha.com - February 15 at 5:23 PM |
| Zacks: Analysts Expect Scpharmaceuticals Inc (SCPH) to Post -$0.53 EPS
www.americanbankingnews.com - February 14 at 3:10 PM |
| Scpharmaceuticals (SCPH) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 14 at 1:46 PM |
| scPharmaceuticals Inc. to Present at the 7th Annual Leerink Partners Global Healthcare Conference
finance.yahoo.com - February 6 at 8:58 AM |
| Research Analysts Set Expectations for Scpharmaceuticals Inc's FY2022 Earnings (SCPH)
www.americanbankingnews.com - January 29 at 8:50 AM |
| scPharmaceuticals, Inc.'s Quiet Period To End on December 27th (NASDAQ:SCPH)
www.americanbankingnews.com - December 20 at 1:06 AM |
| BMO Capital Markets Initiates Coverage on scPharmaceuticals (SCPH)
www.americanbankingnews.com - December 18 at 12:56 AM |
| scPharmaceuticals (SCPH) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - December 17 at 10:44 PM |
| scPharmaceuticals, Inc. (SCPH) Forecasted to Earn FY2017 Earnings of ($2.23) Per Share
www.americanbankingnews.com - December 14 at 6:50 AM |
| Research Analysts Offer Predictions for scPharmaceuticals, Inc.'s Q3 2017 Earnings (SCPH)
www.americanbankingnews.com - December 14 at 6:26 AM |
| scPharmaceuticals (SCPH) Now Covered by Analysts at Jefferies Group
www.americanbankingnews.com - December 12 at 9:04 AM |
 | BRIEF-Ra Capital Management Reports 16.2 Percent Passive Stake In Scpharmaceuticals
www.reuters.com - December 12 at 8:16 AM |
| scPharmaceuticals Inc. to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 12 at 8:16 AM |
| scPharmaceuticals Inc. Announces Closing of Over-Allotment Option in its Initial Public Offering
finance.yahoo.com - December 7 at 7:04 PM |
| scPharmaceuticals Inc. Announces Closing of Initial Public Offering
finance.yahoo.com - November 29 at 8:11 AM |
| scPharmaceuticals Inc. (SCPH) Major Shareholder Purchases $9,166,668.00 in Stock
www.americanbankingnews.com - November 22 at 4:21 AM |
 | IPO News This Week: A Holiday Break After Another Big Week
247wallst.com - November 20 at 9:36 AM |
 | scPharmaceuticals (SCPH) IPO Opens Fractionally Higher - StreetInsider.com
www.streetinsider.com - November 19 at 9:08 AM |
| scPharmaceuticals (SCPH) IPO Opens Fractionally Higher
www.streetinsider.com - November 18 at 4:54 AM |
| scPharmaceuticals Files To Raise $100 Million In U.S. IPO
seekingalpha.com - November 17 at 8:11 AM |
 | Injectable drug developer scPharmaceuticals prices IPO at $14 low end
www.nasdaq.com - November 17 at 8:11 AM |
 | Food, Fashion, Finance Firms Among 10 To IPO - Benzinga
www.benzinga.com - November 16 at 9:14 AM |
| scPharmaceuticals (SCPH) Announces November 17th IPO
www.americanbankingnews.com - November 9 at 1:26 AM |
Scpharmaceuticals (NASDAQ:SCPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Scpharmaceuticals (NASDAQ:SCPH) Income Statement, Balance Sheet and Cash Flow Statement
Scpharmaceuticals (NASDAQ SCPH) Stock Chart for Monday, April, 23, 2018
Loading chart…
